Literature DB >> 16915233

Can open-source R&D reinvigorate drug research?

Bernard Munos1.   

Abstract

The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?

Entities:  

Mesh：

Year:  2006        PMID： 16915233     DOI： 10.1038/nrd2131

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  21 in total

1.  Open science is a research accelerator.

Authors:  Michael Woelfle; Piero Olliaro; Matthew H Todd
Journal:  Nat Chem       Date:  2011-09-23       Impact factor: 24.427

2.  More medicines for neglected and emerging infectious diseases.

Authors:  Jack Radisch
Journal:  Bull World Health Organ       Date:  2007-08       Impact factor: 9.408

Review 3.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

4.  Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation.

Authors:  Feng Xie
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

5.  Chemical genetics of Plasmodium falciparum.

Authors:  W Armand Guiguemde; Anang A Shelat; David Bouck; Sandra Duffy; Gregory J Crowther; Paul H Davis; David C Smithson; Michele Connelly; Julie Clark; Fangyi Zhu; María B Jiménez-Díaz; María S Martinez; Emily B Wilson; Abhai K Tripathi; Jiri Gut; Elizabeth R Sharlow; Ian Bathurst; Farah El Mazouni; Joseph W Fowble; Isaac Forquer; Paula L McGinley; Steve Castro; Iñigo Angulo-Barturen; Santiago Ferrer; Philip J Rosenthal; Joseph L Derisi; David J Sullivan; John S Lazo; David S Roos; Michael K Riscoe; Margaret A Phillips; Pradipsinh K Rathod; Wesley C Van Voorhis; Vicky M Avery; R Kiplin Guy
Journal:  Nature       Date:  2010-05-20       Impact factor: 49.962

6.  A kernel for the Tropical Disease Initiative.

Authors:  Leticia Ortí; Rodrigo J Carbajo; Ursula Pieper; Narayanan Eswar; Stephen M Maurer; Arti K Rai; Ginger Taylor; Matthew H Todd; Antonio Pineda-Lucena; Andrej Sali; Marc A Marti-Renom
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

7.  Open Data, Open Source and Open Standards in chemistry: The Blue Obelisk five years on.

Authors:  Noel M O'Boyle; Rajarshi Guha; Egon L Willighagen; Samuel E Adams; Jonathan Alvarsson; Jean-Claude Bradley; Igor V Filippov; Robert M Hanson; Marcus D Hanwell; Geoffrey R Hutchison; Craig A James; Nina Jeliazkova; Andrew Sid Lang; Karol M Langner; David C Lonie; Daniel M Lowe; Jérôme Pansanel; Dmitry Pavlov; Ola Spjuth; Christoph Steinbeck; Adam L Tenderholt; Kevin J Theisen; Peter Murray-Rust
Journal:  J Cheminform       Date:  2011-10-14       Impact factor: 5.514

8.  Common characteristics of open source software development and applicability for drug discovery: a systematic review.

Authors:  Christine Ardal; Annette Alstadsæter; John-Arne Røttingen
Journal:  Health Res Policy Syst       Date:  2011-09-28

9.  A kernel for open source drug discovery in tropical diseases.

Authors:  Leticia Ortí; Rodrigo J Carbajo; Ursula Pieper; Narayanan Eswar; Stephen M Maurer; Arti K Rai; Ginger Taylor; Matthew H Todd; Antonio Pineda-Lucena; Andrej Sali; Marc A Marti-Renom
Journal:  PLoS Negl Trop Dis       Date:  2009-04-21

10.  Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases.

Authors:  William L Scott; Martin J O'Donnell
Journal:  J Comb Chem       Date:  2009 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.